I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Bachy, E
487
results:
Search for persons
X
Format
Online (487)
Mediatypes
Articles (Online) (90)
OpenAccess-fulltext (397)
Languages
english (334)
more...
french (7)
less...
Sorted by: Relevance
Sorted by: Year
?
1
Safety and efficacy of odronextamab in patients with relaps..:
Kim, T.M.
;
Taszner, M.
;
Novelli, S.
...
Annals of Oncology. , 2024
Link:
https://doi.org/10.1016/..
?
2
ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSL..:
Camus, V.
;
Thieblemont, C.
;
Gaulard, P.
...
Hematological Oncology. 41 (2023) S2 - p. 77-78 , 2023
Link:
https://doi.org/10.1002/..
?
3
Transfusion needs after CD19 CAR T‐cells for large B‐cell l..:
Vic, S.
;
Thibert, J.
;
Bachy, E.
...
Hematological Oncology. 41 (2023) S2 - p. 534-536 , 2023
Link:
https://doi.org/10.1002/..
?
4
ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULA..:
Novelli, S.
;
Luminari, S.
;
Taszner, M.
...
Hematological Oncology. 41 (2023) S2 - p. 121-122 , 2023
Link:
https://doi.org/10.1002/..
?
5
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIB..:
Hertzberg, M.
;
Kalac, M.
;
Cheah, C. Y.
...
Hematological Oncology. 41 (2023) S2 - p. 131-132 , 2023
Link:
https://doi.org/10.1002/..
?
6
Cell‐free DNA sequencing allows the identification of the m..:
Sako, N.
;
Delfau, M.
;
Bachy, E.
...
Hematological Oncology. 41 (2023) S2 - p. 338-339 , 2023
Link:
https://doi.org/10.1002/..
?
7
Functional precision oncology for follicular lymphoma with ..:
Zala, M.
;
Lipinski, B.
;
Costechareyre, C.
...
Hematological Oncology. 41 (2023) S2 - p. 549-549 , 2023
Link:
https://doi.org/10.1002/..
?
8
TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTI..:
Cho, S.
;
Kim, T. M.
;
Taszner, M.
...
Hematological Oncology. 41 (2023) S2 - p. 846-847 , 2023
Link:
https://doi.org/10.1002/..
?
9
RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES ..:
Rebaud, L.
;
Capobianco, N.
;
Spottiswoode, B.
...
Hematological Oncology. 41 (2023) S2 - p. 94-95 , 2023
Link:
https://doi.org/10.1002/..
?
10
GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY..:
Dickinson, M.
;
Carlo‐Stella, C.
;
Morschhauser, F.
...
Hematological Oncology. 41 (2023) S2 - p. 144-146 , 2023
Link:
https://doi.org/10.1002/..
?
11
Long‐term efficacy and safety of zanubrutinib (ZANU) in rel..:
Trotman, J.
;
Tedeschi, A.
;
Hu, B.
...
Hematological Oncology. 41 (2023) S2 - p. 390-392 , 2023
Link:
https://doi.org/10.1002/..
?
12
CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY FOLLICULAR HE..:
Loyaux, R.
;
Sako, N.
;
Quang, V. Tran
...
Hematological Oncology. 41 (2023) S2 - p. 108-110 , 2023
Link:
https://doi.org/10.1002/..
?
13
NATHALI‐01: A PHASE 1/2A TRIAL OF UCART20X22, AN ALLOGENEIC..:
Bachy, E.
;
Ramakrishnan, A.
;
Thieblemont, C.
...
Hematological Oncology. 41 (2023) S2 - p. 825-826 , 2023
Link:
https://doi.org/10.1002/..
?
14
OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGAS..:
Michot, J. M.
;
Chavez, J.
;
Carpio, C.
...
Hematological Oncology. 41 (2023) S2 - p. 134-136 , 2023
Link:
https://doi.org/10.1002/..
?
15
AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐..:
Houot, R.
;
Bachy, E.
;
Cartron, G.
...
Hematological Oncology. 41 (2023) S2 - p. 147-148 , 2023
Link:
https://doi.org/10.1002/..
1-15